NO20060654L - PPAR-aktiverende forbindelse og farmasoytisk blanding inneholdende samme - Google Patents
PPAR-aktiverende forbindelse og farmasoytisk blanding inneholdende sammeInfo
- Publication number
- NO20060654L NO20060654L NO20060654A NO20060654A NO20060654L NO 20060654 L NO20060654 L NO 20060654L NO 20060654 A NO20060654 A NO 20060654A NO 20060654 A NO20060654 A NO 20060654A NO 20060654 L NO20060654 L NO 20060654L
- Authority
- NO
- Norway
- Prior art keywords
- same
- group
- pharmaceutical composition
- composition containing
- activating compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000003213 activating effect Effects 0.000 title abstract 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 102000023984 PPAR alpha Human genes 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Det er beskrevet en forbindelse for selektiv aktivering av PPARa som er representert ved den generelle formel (1) (hvor R, og R2, som kan være like eller forskjellige, representerer et hydrogenatom eller lignende; R3a, R3b, R4a og R4b, kan være like eller forskjellige, og representerer et hydrogenatom eller lignende; X representerer et oksygenatom eller lignende; Y representerer et oksygenatom, S(O)i (I er tallene 0 til 2), en karbonylgruppe, en karbonylaminogruppe, en aminokarbonylgruppe, en sulfonylaminogruppe eller en NH-gruppe; Z representerer CH eller lignende; n er tallene 1 til 6; og m er tallene 2 til 6) eller et salt derav. Det er også beskrevet et terapeutisk medikament inneholdende en slik forbindelse.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49935703P | 2003-09-03 | 2003-09-03 | |
| JP2003317353 | 2003-09-09 | ||
| JP2003364817 | 2003-10-24 | ||
| PCT/JP2004/012750 WO2005023777A1 (ja) | 2003-09-03 | 2004-09-02 | Ppar活性化化合物及びこれを含有する医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20060654L true NO20060654L (no) | 2006-04-26 |
| NO335823B1 NO335823B1 (no) | 2015-02-23 |
Family
ID=34279568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060654A NO335823B1 (no) | 2003-09-03 | 2006-02-09 | PPAR-aktiverende forbindelse samt anvendelse derav, og terapeutisk medikament inneholdende samme |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7109226B2 (no) |
| EP (1) | EP1661890B1 (no) |
| JP (2) | JP4226005B2 (no) |
| KR (1) | KR101160808B1 (no) |
| AU (1) | AU2004270538C1 (no) |
| BR (1) | BRPI0413991B8 (no) |
| CA (1) | CA2535749C (no) |
| CY (1) | CY1111867T1 (no) |
| EA (1) | EA009374B1 (no) |
| HR (1) | HRP20110009T1 (no) |
| IL (1) | IL173639A (no) |
| MX (1) | MXPA06002435A (no) |
| NO (1) | NO335823B1 (no) |
| NZ (1) | NZ545692A (no) |
| PL (1) | PL1661890T3 (no) |
| TW (1) | TWI324599B (no) |
| WO (1) | WO2005023777A1 (no) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004111077A1 (en) * | 2003-06-18 | 2004-12-23 | Tranzyme Pharma Inc. | Macrocyclic antagonists of the motilin receptor |
| CA2533818C (en) * | 2003-07-31 | 2015-03-17 | Tranzyme Pharma, Inc. | Spatially-defined macrocyclic compounds useful for drug discovery |
| US7398116B2 (en) | 2003-08-11 | 2008-07-08 | Veran Medical Technologies, Inc. | Methods, apparatuses, and systems useful in conducting image guided interventions |
| US7301033B2 (en) * | 2005-01-27 | 2007-11-27 | Kowa Co., Ltd. | PPAR-activating compound |
| WO2006090768A1 (ja) * | 2005-02-23 | 2006-08-31 | Kowa Co., Ltd. | 光学活性ｐｐａｒ活性化化合物及びその製造中間体の製造法 |
| US7538242B2 (en) | 2005-03-01 | 2009-05-26 | Kowa Co., Ltd. | Optically active PPAR-activating compound intermediate and method for producing same |
| JP4926955B2 (ja) * | 2005-05-31 | 2012-05-09 | 興和株式会社 | 光学活性ｐｐａｒ活性化化合物及びその製造中間体の製造法 |
| WO2007013555A1 (ja) | 2005-07-28 | 2007-02-01 | Kowa Co., Ltd. | 光学活性２－ヒドロキシ酪酸エステルの製造法 |
| US8088733B2 (en) * | 2006-07-06 | 2012-01-03 | Tranzyme Pharma Inc. | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
| WO2008094860A2 (en) | 2007-01-30 | 2008-08-07 | Allergan, Inc. | Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists |
| TWI407955B (zh) * | 2007-03-29 | 2013-09-11 | Kowa Co | 高脂血症之預防及／或治療劑 |
| JP5679458B2 (ja) * | 2009-09-28 | 2015-03-04 | 興和株式会社 | 内臓脂肪重量の低下剤 |
| TWI425948B (zh) * | 2012-01-20 | 2014-02-11 | 優生生物科技股份有限公司 | Compositions for the inhibition or killing of Porphyromonas gingivalis and their use for the alleviation or treatment of periodontal disease and other diseases |
| CA2901650C (en) | 2012-09-27 | 2021-05-04 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
| CN105102415B (zh) | 2013-03-29 | 2017-03-15 | 兴和株式会社 | 2‑羟基羧酸或其衍生物的光学纯度提高法 |
| TWI696462B (zh) | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| KR20230050472A (ko) | 2013-08-28 | 2023-04-14 | 교와 가부시키가이샤 | 지질 이상증 치료제 |
| US10669296B2 (en) * | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| TW201618777A (zh) * | 2014-09-26 | 2016-06-01 | 興和股份有限公司 | 脂質異常症治療劑 |
| TWI691331B (zh) * | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| WO2017082393A1 (ja) * | 2015-11-12 | 2017-05-18 | 学校法人 聖マリアンナ医科大学 | 緑内障予防治療剤 |
| PT3275438T (pt) | 2016-07-29 | 2021-01-25 | Kowa Co | Métodos de prevenção de eventos cardiovasculares em populações dislipidémicas de risco residual |
| JPWO2018037593A1 (ja) | 2016-08-25 | 2019-06-20 | 興和株式会社 | Ｐｂｃの治療剤 |
| JP2019059673A (ja) * | 2016-08-25 | 2019-04-18 | 興和株式会社 | Ｐｂｃの治療剤 |
| HUE071625T2 (hu) | 2017-01-11 | 2025-09-28 | Kowa Co | Pemafibrát SGLT2-gátlóval kombinációban, ami májbetegségek, zsírmáj profilaktikus vagy terápiás kezelésére szolgál |
| US10314825B2 (en) | 2017-02-24 | 2019-06-11 | Kowa Company, Ltd. | Agent for treatment of PBC |
| EP3646865A4 (en) | 2017-06-30 | 2021-03-17 | Kowa Company, Ltd. | MEDICINE |
| US11298340B2 (en) | 2017-06-30 | 2022-04-12 | Kowa Company, Ltd. | Pharmaceutical composition |
| WO2019004451A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| CN110809470A (zh) | 2017-06-30 | 2020-02-18 | 兴和株式会社 | 医药品 |
| US20200121648A1 (en) * | 2017-06-30 | 2020-04-23 | Kowa Company, Ltd. | Pharmaceutical composition |
| EP3646864A4 (en) | 2017-06-30 | 2021-03-17 | Kowa Company, Ltd. | PEMAFIBRATE MEDICINAL PRODUCT |
| SMT202400478T1 (it) | 2017-06-30 | 2025-01-14 | Kowa Co | Composizione farmaceutica |
| US11344535B2 (en) | 2017-06-30 | 2022-05-31 | Kowa Company, Ltd. | Pharmaceutical composition |
| JP7402687B2 (ja) * | 2017-06-30 | 2023-12-21 | 興和株式会社 | 医薬組成物 |
| JP6959049B2 (ja) * | 2017-06-30 | 2021-11-02 | 興和株式会社 | 新規低アルブミン血症改善薬 |
| AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
| JP2021506907A (ja) * | 2017-12-21 | 2021-02-22 | 興和株式会社 | 高トリグリセライド血症の治療方法 |
| US11446282B2 (en) | 2017-12-21 | 2022-09-20 | Kowa Company, Ltd. | Methods of treating mixed dyslipidemia and hypertriglycertdemia |
| EP3732168A1 (en) | 2017-12-27 | 2020-11-04 | Teva Pharmaceuticals International GmbH | Solid state forms of pemafibrate |
| WO2019216313A1 (ja) | 2018-05-08 | 2019-11-14 | 国立大学法人岡山大学 | 心血管疾患に有用な医薬 |
| JP7058763B2 (ja) * | 2018-12-27 | 2022-04-22 | 興和株式会社 | 医薬品 |
| WO2020138406A1 (ja) | 2018-12-27 | 2020-07-02 | 興和株式会社 | 医薬組成物 |
| JP7058762B2 (ja) * | 2018-12-27 | 2022-04-22 | 興和株式会社 | 医薬品 |
| JP2020105174A (ja) * | 2018-12-27 | 2020-07-09 | 興和株式会社 | 医薬組成物 |
| MX2022007164A (es) | 2019-12-13 | 2022-09-12 | Inspirna Inc | Sales metálicas y usos de estas. |
| EP4327826A4 (en) | 2021-04-20 | 2025-04-23 | Kowa Company, Ltd. | COMBINATION MEDICINE FOR THE PREVENTION/TREATMENT OF DYSLIPIDEMIA OR CARDIOVASCULAR DISEASE |
| AU2022264289A1 (en) | 2021-04-28 | 2023-11-02 | Kowa Company, Ltd. | Blood carnitine-increasing agent |
| CN118946357A (zh) | 2022-03-31 | 2024-11-12 | 学校法人慈惠大学 | 呼吸系统疾病治疗剂 |
| KR20250029790A (ko) | 2022-07-06 | 2025-03-05 | 교와 가부시키가이샤 | 혈중 마이오스타틴 저하제 |
| US20260014122A1 (en) | 2022-07-15 | 2026-01-15 | Kowa Company, Ltd. | Drug for lowering blood ldl cholesterol |
| WO2024201358A1 (en) * | 2023-03-31 | 2024-10-03 | Ami Lifesciences Private Limited | A process for the preparation of pemafibrate and intermediates thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS593465B2 (ja) * | 1974-06-04 | 1984-01-24 | 藤沢薬品工業株式会社 | チカンアミノアルキルチカンフエノキシカルボンサンルイノ セイゾウホウ |
| JPS6025425B2 (ja) * | 1975-03-06 | 1985-06-18 | 藤沢薬品工業株式会社 | 置換フエノキシ脂肪酸類の合成法 |
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| AU2002224139A1 (en) * | 2000-12-05 | 2002-06-18 | Nippon Chemiphar Co. Ltd. | Ppar (peroxisome proliferator activated receptor) activators |
| DE10151390A1 (de) * | 2001-10-18 | 2003-05-08 | Bayer Ag | Essigsäurederivate |
| JP4383177B2 (ja) * | 2002-03-01 | 2009-12-16 | スミスクライン ビーチャム コーポレーション | ｈＰＰＡＲ活性化剤 |
| US6653334B1 (en) * | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
-
2004
- 2004-09-02 WO PCT/JP2004/012750 patent/WO2005023777A1/ja not_active Ceased
- 2004-09-02 PL PL04772699T patent/PL1661890T3/pl unknown
- 2004-09-02 EP EP04772699A patent/EP1661890B1/en not_active Expired - Lifetime
- 2004-09-02 HR HR20110009T patent/HRP20110009T1/hr unknown
- 2004-09-02 CA CA2535749A patent/CA2535749C/en not_active Expired - Fee Related
- 2004-09-02 MX MXPA06002435A patent/MXPA06002435A/es active IP Right Grant
- 2004-09-02 EA EA200600527A patent/EA009374B1/ru not_active IP Right Cessation
- 2004-09-02 JP JP2005513668A patent/JP4226005B2/ja not_active Expired - Lifetime
- 2004-09-02 KR KR1020067003950A patent/KR101160808B1/ko not_active Expired - Fee Related
- 2004-09-02 AU AU2004270538A patent/AU2004270538C1/en not_active Ceased
- 2004-09-02 NZ NZ545692A patent/NZ545692A/xx not_active IP Right Cessation
- 2004-09-02 BR BRPI0413991A patent/BRPI0413991B8/pt not_active IP Right Cessation
- 2004-09-03 US US10/933,467 patent/US7109226B2/en not_active Expired - Lifetime
- 2004-09-03 TW TW093126702A patent/TWI324599B/zh not_active IP Right Cessation
-
2006
- 2006-02-09 IL IL173639A patent/IL173639A/en active IP Right Grant
- 2006-02-09 NO NO20060654A patent/NO335823B1/no not_active IP Right Cessation
- 2006-04-20 US US11/407,076 patent/US7183295B2/en not_active Expired - Lifetime
-
2008
- 2008-10-31 JP JP2008281020A patent/JP4931893B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-31 CY CY20111100343T patent/CY1111867T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20060654L (no) | PPAR-aktiverende forbindelse og farmasoytisk blanding inneholdende samme | |
| BG108089A (en) | Pyridine matrix metalloproteinase inhibitors | |
| NO20083026L (no) | Terapeutisk middel for diabetes | |
| NO20070468L (no) | Sammensetninger og fremgangsmater for behandling av dyslipidemi | |
| NO20045369L (no) | Nye, substituerte sulfamatanticonvulsivaderivater | |
| EA200600620A1 (ru) | Набор для ингаляции с ингаляционным порошком, содержащим тиотропий | |
| HUP0302792A2 (hu) | Dipeptidil peptidáz ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| WO2001083459A3 (en) | Uracil substituted phenyl sulfamoyl carboxamides | |
| NO20011351L (no) | Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav | |
| DK1483246T3 (da) | 5-Substituerede alkylaminopyrazolderivater som pesticider | |
| NO20070570L (no) | Forbindelser. | |
| WO2005097788A3 (en) | Sulfonamides and uses thereof | |
| NO20060426L (no) | Kannabinoid reseptormodulator | |
| NO20063576L (no) | 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes | |
| WO2002092072A3 (en) | Drugs for the treatment of the alzheimer disease | |
| NO20083790L (no) | Nye terapeutiske kombinasjoner for behandling eller forebygging av psykotiske lidelser | |
| ATE441630T1 (de) | Substituierte cyclopenten-verbindungen | |
| AU2003294082A1 (en) | Composition comprising a carbamic acid derivative, its use as cosmetic and medicine | |
| NO20043211L (no) | Imidazo [1,2-a]pyridinderivat | |
| SE0200198D0 (sv) | New use | |
| DE60227421D1 (de) | Rmazeutische zusammensetzung und verwendung davon | |
| NO20053592L (no) | Vann opploslige fenylpyridazinderivater og medikamenter inneholdende disse. | |
| NO20002575L (no) | Substituerte oksimer som neurokininantagonister | |
| BRPI0409951A (pt) | derivados de anilina, sua produção e uso como agentes farmacêuticos | |
| DE60227008D1 (de) | Neue thiophenacylhydrazinoderivate, verfahren zu deren herstellung, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen und neue anwendungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |